Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an update.
Clarity Pharmaceuticals has issued 120,000 fully paid ordinary shares following the exercise of options, without the need for investor disclosure under the Corporations Act. This move reflects the company’s compliance with relevant legal provisions and indicates a strategic step in its operational and financial activities, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company that specializes in innovative radiopharmaceuticals. It focuses on developing targeted copper theranostics using its SAR Technology Platform for treating cancer in both children and adults.
Average Trading Volume: 3,000,888
Technical Sentiment Signal: Sell
Current Market Cap: A$668.4M
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.